Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

KEYNOTE-361 Investigators

Research output: Contribution to journal › Article › peer-review

137 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences